This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D68.6 | Synonyms: Antiphospholipid antibody syndrome, APS, Hughes syndrome, lupus anticoagulant syndrome
The history of antiphospholipid syndrome dates back to the 1950s, when a tendency toward thrombosis and miscarriage was observed in a group of patients with false-positive syphilis serology (VDRL). In 1952, Conley and Hartmann described a substance in the plasma of patients with systemic lupus erythematosus (SLE) that prolonged the prothrombin time (PT) and partial thromboplastin time (PTT), which was later named lupus anticoagulant (LA). The paradoxical property that, unlike its anticoagulant effect in vitro, it actually causes thrombosis in vivo gradually came to be recognized.
In 1983, Graham Hughes, Aziz Gharavi, and colleagues in the UK systematically described the clinical significance of anticardiolipin antibodies (aCL) in patients with and without systemic lupus erythematosus and proposed the disease as an independent syndrome. Since 1987, the syndrome has also been called 'Hughes syndrome' after Graham Hughes. Diagnostic criteria were first formally proposed at an international workshop held in Sapporo, Japan, in 1999, and were revised in 2006 as the Sydney criteria (Miyakis criteria), which remain in international use today.
In the early 1990s, McNeil and colleagues showed that the main target antigen of anticardiolipin antibodies is not cardiolipin itself but β2-glycoprotein I (β2GPI). This discovery was a landmark turning point in understanding the pathogenesis of antiphospholipid syndrome and led to the inclusion of anti-β2GPI antibodies as an independent diagnostic criterion.
Antiphospholipid syndrome is an autoimmune disease in which autoantibodies against phospholipid-binding proteins, particularly β2-glycoprotein I (β2GPI) and prothrombin, are repeatedly detected and cause thrombosis or pregnancy complications. The major antiphospholipid antibodies include lupus anticoagulant (LA), anticardiolipin antibodies (aCL IgG/IgM), and anti-beta2-glycoprotein I antibodies (anti-β2GPI IgG/IgM).
Primary APS occurs independently without other autoimmune disease. Secondary APS occurs in association with systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren syndrome, and other autoimmune diseases, with SLE being the most common association. Antiphospholipid antibodies are detected in about 30–40% of patients with SLE, and clinical APS develops in some of them.
Infections (syphilis, HIV, hepatitis B/C, parvovirus), certain drugs (hydralazine, quinidine, chlorpromazine), and malignancies can induce the production of antiphospholipid antibodies. However, such cases are known to be transient with a low risk of thrombosis, and antibody positivity often disappears on retesting after 12 weeks.
Antiphospholipid syndrome is not a single-gene disorder, and a multifactorial genetic predisposition is involved. Associations with HLA types have been reported, and HLA-DR4, HLA-DR7, HLA-DQ6, HLA-DQ7, and others have been suggested to be associated with the production of anticardiolipin antibodies and anti-beta2-glycoprotein I antibodies.
There are studies suggesting that polymorphisms in the β2GPI gene (APOH gene, located at 17q23-24) may be associated with the risk of developing APS. In particular, the Val247Leu polymorphism has been reported in some studies to be associated with anti-β2GPI antibody production and thrombosis risk. However, no single-gene variant causing APS has been identified to date.
Some family studies have reported familial clustering of APS, but it does not follow a simple Mendelian inheritance pattern. There are reports that the rate of antiphospholipid antibody positivity in first-degree relatives of patients with APS is higher than in the general population. A family history of autoimmune disease in general may increase the risk of developing APS.
The prevalence of antiphospholipid antibodies in the general population is estimated at about 1–5%. However, not all antibody positivity meets the diagnostic criteria for clinical APS. The prevalence of clinical APS is estimated at about 50 per 100,000 population, with an annual incidence of about 2–5 per 100,000.
APS occurs more commonly in women, with a female-to-male ratio of about 3–5:1. The age of onset is highest during the reproductive years of 15–50, but it can also occur in children and the elderly. In men, arterial thrombosis (stroke, myocardial infarction) is relatively more common.
In Korea, APS is classified as a rare autoimmune disease, and accurate prevalence statistics are lacking. According to registry studies of the Korean College of Rheumatology and the Korean Society of Hematology, antiphospholipid antibodies are detected in about 20–30% of patients with SLE. In Korea as well, differentiation of APS in patients with unexplained thrombosis and recurrent miscarriage is recognized as important, and early diagnosis is increasing as access to diagnosis improves.
Antiphospholipid antibodies are reported to be detected in about 10–15% of patients with unexplained arterial thrombosis, about 10–20% of patients with venous thromboembolism, and about 15–20% of women with recurrent miscarriage. There are also studies showing that APS accounts for about 20% of stroke patients of young age.
β2GPI is a protein that binds to anionic phospholipids and regulates coagulation reactions. Anti-β2GPI antibodies recognize β2GPI when it is bound to phospholipid membranes or endothelial cell surfaces and induce endothelial cell activation, platelet activation, and increased monocyte tissue factor expression. This promotes thrombus formation.
Lupus anticoagulant inhibits phospholipid-dependent coagulation reactions in vitro but actually causes thrombosis in vivo. This is because it promotes thrombus formation by inhibiting the function of anticoagulant proteins (protein C, protein S, antithrombin), inhibiting fibrinolysis, and activating endothelial cells.
Complement activation plays an important role in the development of pregnancy-related complications. Antiphospholipid antibodies activate complement (C3a, C5a) in the placenta, causing trophoblast damage, neutrophil infiltration, and inflammatory responses, which are the mechanisms of early pregnancy loss and late pregnancy complications.
Anti-β2GPI antibodies directly activate platelets via the platelet surface apoER2 receptor or GPIbα, contributing to increased platelet aggregation and promotion of thrombus formation. This multi-pathway promotion of thrombosis is at the core of the mechanism of thrombosis in APS.
Venous thrombosis (deep vein thrombosis, pulmonary embolism) is the most common, with leg swelling, pain, redness, sudden dyspnea, and chest pain as the main symptoms. Arterial thrombosis includes stroke (including transient ischemic attack), myocardial infarction, and peripheral arterial occlusion. When stroke occurs at a young age, APS should be strongly suspected. Atypical thrombosis (mesenteric thrombosis, adrenal thrombosis, retinal thrombosis) may also occur.
Recurrent miscarriage (before 10 weeks of gestation, 3 or more times), unexplained fetal death after 10 weeks of gestation, and preterm delivery before 34 weeks of gestation (due to preeclampsia, eclampsia, or severe placental insufficiency) are characteristic. Intrauterine growth restriction and oligohydramnios may also occur during pregnancy. Obstetric APS results in recurrent pregnancy loss without treatment.
Mild to moderate thrombocytopenia (platelet count 50,000–150,000/μL) develops in about 20–40% of patients with APS. Spontaneous bleeding is usually rare, but differentiation from immune thrombocytopenia (ITP) is necessary. Thrombocytopenia may paradoxically increase the risk of thrombosis.
Skin findings may include livedo reticularis and skin ulcers. Neurological symptoms reported include cognitive impairment, headache (including migraine), epilepsy, and chorea. Cardiac valve disease (Libman-Sacks endocarditis), nephropathy, and adrenal insufficiency may also be associated with APS.
Livedo reticularis: a reticular violaceous discoloration of the skin reflecting vascular occlusion. Swelling, erythema, and tenderness at the site of deep vein thrombosis. Focal neurological deficits due to stroke (hemiparesis, dysarthria, etc.). Valvular murmurs may be heard on cardiac auscultation. Splenomegaly is rarely present.
Prolongation on lupus anticoagulant (LA) testing (dRVVT, aPTT-based). Anticardiolipin antibodies (aCL IgG/IgM) at medium or high titer (>40 GPL or MPL units, or >99th percentile). Anti-β2GPI antibodies (IgG/IgM) >99th percentile. Thrombocytopenia, positive direct Coombs test (when accompanied by autoimmune hemolytic anemia). Isolated aPTT prolongation (not corrected on mixing study) is characteristic.
Multiple ischemic strokes and white matter changes observed on brain MRI/MRA. Libman-Sacks endocarditis (valve thickening, nodules) on echocardiography. Deep vein thrombosis confirmed by lower-extremity venous ultrasound or CT venography. Pulmonary embolism confirmed by pulmonary CT angiography.
Antiphospholipid antibody screening is recommended in the following cases: ① patients with unexplained venous thromboembolism, ② unexplained arterial thrombosis at a young age under 50 years, ③ thrombosis at atypical sites (mesenteric, hepatic vein, renal vein, etc.), ④ recurrent miscarriage (3 or more times before 10 weeks of gestation), ⑤ unexplained fetal death after 10 weeks of gestation, ⑥ unexplained thrombocytopenia, ⑦ when thrombosis or obstetric complications occur in autoimmune diseases such as SLE.
It is recommended to test for all 3 antibodies: lupus anticoagulant testing (dRVVT, aPTT-based), anticardiolipin antibodies (aCL IgG/IgM ELISA), and anti-β2GPI antibodies (IgG/IgM ELISA). All tests should be reconfirmed at an interval of 12 weeks or more after the first positive result to exclude transient antibody positivity.
At tertiary hospitals in Korea, all 3 antiphospholipid antibody tests are available and covered by health insurance, so access is good. Lupus anticoagulant testing is performed in specialized laboratories, and caution is needed in interpreting test results while taking anticoagulants.
The diagnosis of APS requires that at least 1 clinical criterion and at least 1 laboratory criterion be met.
| Category | Criteria | Details |
|---|---|---|
| Clinical criterion ① | Vascular thrombosis | Arterial, venous, or small-vessel thrombosis confirmed by imaging or histology on 1 or more occasions |
| Clinical criterion ② | Pregnancy morbidity (a) | 1 or more unexplained deaths of a morphologically normal fetus after 10 weeks of gestation |
| Clinical criterion ② | Pregnancy morbidity (b) | Premature birth before 34 weeks of gestation due to preeclampsia/eclampsia/placental insufficiency |
| Clinical criterion ② | Pregnancy morbidity (c) | 3 or more consecutive unexplained spontaneous miscarriages before 10 weeks of gestation |
| Laboratory criterion ① | Lupus anticoagulant (LA) positive | Positive on 2 or more occasions 12 weeks apart |
| Laboratory criterion ② | aCL IgG/IgM at medium or high titer | >40 GPL/MPL or >99th percentile, on 2 or more occasions 12 weeks apart |
| Laboratory criterion ③ | Anti-β2GPI IgG/IgM >99th percentile | Positive on 2 or more occasions 12 weeks apart |
Positivity for all 3 antibodies, LA, aCL, and anti-β2GPI (triple positivity), defines the high-risk group with the highest risk of recurrent thrombosis and obstetric complications. Single antibody positivity, especially isolated low-titer aCL positivity, has a low association with clinical APS.
Differentiation is needed from inherited thrombophilia (Factor V Leiden, prothrombin G20210A, protein C, protein S, or antithrombin deficiency), homocysteinemia, polycythemia vera/essential thrombocythemia, thrombotic thrombocytopenic purpura (TTP), heparin-induced thrombocytopenia (HIT), and others.
In patients with APS who have had venous thromboembolism, long-term anticoagulation is given with a vitamin K antagonist (warfarin), with a target INR of 2.0–3.0. When arterial thrombosis (especially stroke) has occurred, maintaining a target INR of 2.0–3.0 or adding aspirin is considered. Because the TRAPS trial showed that direct oral anticoagulants (DOACs) carry a higher risk of thrombosis recurrence than warfarin in triple-positive high-risk APS, they are currently not recommended in high-risk APS.
In patients with APS during pregnancy, the combination of low-dose aspirin (75–100 mg/day) and prophylactic or therapeutic doses of low-molecular-weight heparin (LMWH) is the standard treatment. This combination therapy improves the live birth rate to about 70–80%. Because warfarin has fetal toxicity in early pregnancy (especially weeks 6–12), it is replaced by LMWH during pregnancy.
To prevent thrombosis recurrence, modifiable risk factors (smoking, oral contraceptives, obesity, hypertension) are actively managed. Hydroxychloroquine has an effect in preventing thrombosis recurrence in patients with APS accompanied by SLE and is generally recommended. Statins are being studied for their benefit in APS because of their vascular endothelial protective effects.
A rare severe form in which multiple organ thromboses occur within a short period. It is treated with a combination of anticoagulants, high-dose steroids, plasma exchange, intravenous immunoglobulin (IVIG), and rituximab. It is an emergency with a mortality rate of about 30–50%, requiring immediate intensive care.
When anticoagulation is discontinued, the rate of thrombosis recurrence within the first 2 years reaches about 50%. The risk of recurrence is highest with triple positivity (LA + aCL + anti-β2GPI all positive), arterial thrombosis, accompanying SLE, and 2 or more previous thrombotic events. In single-antibody positivity and low-risk groups, the risk of recurrence is relatively low.
APS is a chronic disease, and appropriate anticoagulation can prevent much of the recurrence of thrombosis. However, bleeding complications of long-term warfarin therapy, management of cardiovascular risk factors, and neurocognitive decline affect the long-term prognosis. In patients with APS accompanied by SLE, worsening of the prognosis due to complications of SLE itself must also be considered.
With appropriate treatment (aspirin + LMWH), the live birth rate is about 70–80%. When recurrent pregnancy loss persists despite treatment, rescue therapies such as adding hydroxychloroquine, rIVIg, and plasma exchange are considered.
In those who are antiphospholipid antibody positive but do not meet the criteria for clinical APS (asymptomatic carriers), low-dose aspirin is recommended for high-risk groups (triple positivity, accompanying SLE, multiple cardiovascular risk factors). It is important to eliminate additional thrombotic risk factors such as smoking, obesity, and oral contraceptive use.
In patients with APS who have had thrombosis, maintaining long-term anticoagulation (warfarin) is key. Regular INR monitoring, maintenance of the therapeutic INR range, and surveillance for bleeding complications are necessary. Discontinuation of anticoagulation should be decided after thorough consultation with a specialist.
In patients with APS, careful attention to anticoagulant management is needed in triggering situations such as surgery, infection, and delivery. In particular, when anticoagulants must be temporarily discontinued, bridging anticoagulation should be considered.